These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25822447)

  • 1. Neutrophil-lymphocyte ratio in Crohn's disease patients predicts sustained response to infliximab 52-week therapy.
    Wlodarczyk MK; Sobolewska AE; Stec-Michalska K; Fichna JJ; Wisniewska-Jarosinska ME
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):127-8. PubMed ID: 25822447
    [No Abstract]   [Full Text] [Related]  

  • 2. Mean Platelet Volume in Crohn's Disease Patients Predicts Sustained Response to a 52-Week Infliximab Therapy: A Pilot Study.
    Sobolewska A; Włodarczyk M; Stec-Michalska K; Fichna J; Wiśniewska-Jarosińska M
    Dig Dis Sci; 2016 Feb; 61(2):542-9. PubMed ID: 26441277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neutrophil-lymphocyte ratio at 14th week predicts loss of response to 52-week infliximab therapy in patients with Crohn's disease].
    Qian G; Hongxia D; Jin LI
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Apr; 40(4):453-458. PubMed ID: 32895126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease.
    Baert F; Moortgat L; Van Assche G; Caenepeel P; Vergauwe P; De Vos M; Stokkers P; Hommes D; Rutgeerts P; Vermeire S; D'Haens G; ;
    Gastroenterology; 2010 Feb; 138(2):463-8; quiz e10-1. PubMed ID: 19818785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of infliximab in the treatment of Crohn's disease in children].
    Teng X; Xu LF; Sun M; Guo J
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Oct; 17(10):1088-92. PubMed ID: 26483230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
    Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
    Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of vulval Crohn's disease with infliximab.
    Preston PW; Hudson N; Lewis FM
    Clin Exp Dermatol; 2006 May; 31(3):378-80. PubMed ID: 16681581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of anti-double-strained DNA but not antinuclear antibodies are associated with treatment efficacy and adverse outcomes in Crohn's disease patients treated with anti-TNFα.
    Kiss LS; Lovasz BD; Golovics PA; Vegh Z; Farkas K; Molnar T; Palatka K; Papp M; Mohas A; Szilagyi BK; Fekete SA; Mandel M; Lakatos PL
    J Gastrointestin Liver Dis; 2013 Jun; 22(2):135-40. PubMed ID: 23799211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Platelet count predicts therapeutic response of infliximab for active Crohn's disease].
    Shen H; Xu C; Chen C
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 Jan; 45(1):81-5. PubMed ID: 27045246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA; Villela R; Silverberg MS; Greenberg GR
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous Crohn's disease treated with infliximab and 4 years of follow up.
    Yoong C; Schofield C; Rodins K; Faulkner C
    Australas J Dermatol; 2014 Aug; 55(3):e40-3. PubMed ID: 23772972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Wittmann T
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):265-9. PubMed ID: 23012667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease.
    Kierkuś J; Iwańczak B; Wegner A; Dadalski M; Grzybowska-Chlebowczyk U; Łazowska I; Maślana J; Toporowska-Kowalska E; Czaja-Bulsa G; Mierzwa G; Korczowski B; Czkwianianc E; Żabka A; Szymańska E; Krzesiek E; Więcek S; Sładek M
    J Pediatr Gastroenterol Nutr; 2015 May; 60(5):580-5. PubMed ID: 25564804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission.
    Papamichael K; Vande Casteele N; Gils A; Tops S; Hauenstein S; Singh S; Princen F; Van Assche G; Rutgeerts P; Vermeire S; Ferrante M
    Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1103-10. PubMed ID: 25478919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas?
    Gaertner WB; Decanini A; Mellgren A; Lowry AC; Goldberg SM; Madoff RD; Spencer MP
    Dis Colon Rectum; 2007 Nov; 50(11):1754-60. PubMed ID: 17899271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
    Louis E; Mary JY; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Porcher R; Paintaud G; Piver E; Colombel JF; Lemann M;
    Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of Crohn's disease by infliximab. About 20 cases].
    Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A
    Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab treatment of pediatric refractory Crohn's disease: a case report.
    Akman SA; Arikan C; Sözen G; Oztürk C; Yağci RV
    Turk J Gastroenterol; 2006 Jun; 17(2):133-6. PubMed ID: 16830299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.